TYK2 and cancer: Importantly, the per‐allele estimates presented in this analysis may underestimate the effect of therapeutic TYK2 inhibition on cancer given larger TYK2 reductions achieved by deucravacitinib at doses shown to confer therapeutic benefit (50%‐80% TYK2 inhibition) compared to the <40% expected per copy of the rs34536443 minor allele.21